Pfizer Faces Patent Cliffs, Dismal Outlook for 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: Fool
- Patent Crisis: Pfizer is facing significant challenges with multiple patent expirations over the next two years, including for its best-selling anticoagulant Eliquis, which is expected to exert considerable pressure on revenue and potentially lead to a decline in market value.
- Clinical Trial Delays: The company has yet to produce results from clinical trials for candidates that could replace Eliquis, while sales from its COVID-19 franchise continue to dwindle, further impacting its future revenue growth potential.
- Intensifying Competition: Other healthcare leaders like Vertex Pharmaceuticals and Medtronic are expected to outperform Pfizer in 2026, potentially surpassing its market value, indicating a weakening competitive position for Pfizer in the industry.
- Uncertain Market Outlook: Although Pfizer has the potential to rebound in the future, analysts believe it will take time, and 2026 may not be a pivotal year for recovery, prompting investors to carefully assess its long-term investment value.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDT is 110.47 USD with a low forecast of 90.00 USD and a high forecast of 119.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
21 Analyst Rating
10 Buy
11 Hold
0 Sell
Moderate Buy
Current: 98.690
Low
90.00
Averages
110.47
High
119.00
Current: 98.690
Low
90.00
Averages
110.47
High
119.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
